title: Drug Hepatotoxicity: Newer Agents.
abstract: Idiosyncratic hepatotoxicity is one of the most common reasons for an approved drug being restricted. This article focuses on hepatotoxicity of selected and recently introduced agents, such as, tyrosine kinase inhibitors, monoclonal antibodies, novel oral anticoagulants, newer antiplatelets, antibiotics, anti-diabetics, anti-epileptics, anti-depressants, anti-psychotics and anti-retrovirals. Overall, the incidence of clinically relevant hepatotoxicity from newer agents seems to be lower than that of the older agents. Nevertheless, cases of severe hepatotoxicity have been reported due to some of these newer agents, including, trastuzumab, ipilimumab, infliximab, imatinib, bosutinib, dasatinib, gefitinib, erlotinib, sunitinib, ponatinib, lapatinib, vemurafenib, dabigatran, rivaroxaban, felbamate, lamotrigine, levetiracetam, venlafaxine, duloxetine, darunavir, and maraviroc.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, HUP, Philadelphia, PA 19104, USA; Division of Gastroenterology and Hepatology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Rajavithi Road, Ratchathewi, Bangkok 10400, Thailand.
authors.forename: Chalermrat
authors.initials: C
authors.lastname: Bunchorntavakul
authors.affiliation: Liver Transplantation, Viral Hepatitis Center, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, HUP, Liver Transplant Office, Philadelphia, PA 19104, USA. Electronic address: rajender.reddy@uphs.upenn.edu.
authors.forename: K Rajender
authors.initials: KR
authors.lastname: Reddy
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D004364:Pharmaceutical Preparations; D018570:Risk Assessment; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D044966:Anti-Retroviral Agents; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations
keywords: Antibiotics; Anticoagulants; Antiplatelet; Antiretrovirals; Drug-induced liver injury; Hepatotoxicity; Monoclonal antibodies; Tyrosine kinase inhibitors